"I'm a Survivor": Perceptions of Chronic Disease and Survivorship Among Individuals in Long-Term Remission from Opioid Use Disorder
- PMID: 34027611
- PMCID: PMC8141362
- DOI: 10.1007/s11606-021-06925-z
"I'm a Survivor": Perceptions of Chronic Disease and Survivorship Among Individuals in Long-Term Remission from Opioid Use Disorder
Abstract
Background: While opioid use disorder (OUD) is prevalent, little is known about what patients with OUD in sustained remission think about the chronic disease model of OUD and their perspectives of the cause, course, and ongoing treatment needs of their OUD.
Objective: To (1) examine patient perceptions of the chronic disease model of addiction and disease identity and (2) use an explanatory model framework to explore how these perceptions inform ongoing treatment needs and help maintain abstinence.
Design: Qualitative study of a cross-sectional cohort of patients with OUD in long-term sustained remission currently receiving methadone or buprenorphine. Participants completed a single in-depth, semi-structured individual interview.
Participants: Twenty adults were recruited from two opioid treatment programs and two office-based opioid treatment programs in Baltimore, MD. Half of the participants were Black, had a median (IQR) age of 46.5 (43-52) years and the median (IQR) time since the last non-prescribed opioid was 12 (8-15) years.
Approach: Hybrid deductive-inductive thematic analysis of the transcribed interviews.
Key results: Some participants described a chronic OUD disease identity where they continue to live with OUD. Participants who maintain an OUD identity describe inherent traits or predetermination of developing OUD. Maintaining a disease identity helps them remain vigilant against returning to drug use. Others described a post-OUD/survivor identity where they no longer felt they had OUD, but the experience remains. Each perspective informed attitudes about continued treatment with methadone or buprenorphine and strategies to remain in remission.
Conclusions: The identity that people with OUD in sustained remission maintain was the lens through which they viewed other aspects of their OUD including cause and ongoing treatment needs. An alternative, post-OUD/survivorship model emerged or was accepted by participants who did not identify as currently having OUD. Understanding patient perspectives of OUD identity might improve patient-centered care and improve outcomes.
Keywords: buprenorphine; chronic disease; methadone; opioid use disorder; survivorship.
© 2021. Society of General Internal Medicine.
Conflict of interest statement
The authors declare that they do not have a conflict of interest.
Figures
Similar articles
-
Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.Subst Use Misuse. 2019;54(14):2409-2419. doi: 10.1080/10826084.2019.1653324. Epub 2019 Aug 20. Subst Use Misuse. 2019. PMID: 31429351 Free PMC article.
-
The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants.Subst Use Misuse. 2024;59(2):312-315. doi: 10.1080/10826084.2023.2269571. Epub 2023 Dec 28. Subst Use Misuse. 2024. PMID: 37861246
-
Perceptions of medications, program settings, and drug use histories among individuals engaged in treatment for opioid use disorder.J Addict Dis. 2024 Jan-Mar;42(1):24-32. doi: 10.1080/10550887.2022.2126273. Epub 2022 Nov 3. J Addict Dis. 2024. PMID: 36325942 Free PMC article.
-
Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.PLoS Med. 2019 Dec 31;16(12):e1003002. doi: 10.1371/journal.pmed.1003002. eCollection 2019 Dec. PLoS Med. 2019. PMID: 31891578 Free PMC article.
-
Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.J Stud Alcohol Drugs. 2019 Jul;80(4):393-402. J Stud Alcohol Drugs. 2019. PMID: 31495374 Review.
Cited by
-
Reframing conceptualizations of primary care involvement in opioid use disorder treatment.BMC Prim Care. 2024 Sep 30;25(1):356. doi: 10.1186/s12875-024-02607-x. BMC Prim Care. 2024. PMID: 39350088 Free PMC article.
-
Post-treatment life-trajectories among people who inject drugs who completed hepatitis C treatment with direct acting antivirals: A thematic analysis.Br J Health Psychol. 2025 Sep;30(3):e70005. doi: 10.1111/bjhp.70005. Br J Health Psychol. 2025. PMID: 40650350 Free PMC article.
-
Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages.J Med Internet Res. 2025 Apr 25;27:e71245. doi: 10.2196/71245. J Med Internet Res. 2025. PMID: 40279635 Free PMC article.
-
Patient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative research.BMJ Open. 2024 Dec 4;14(12):e088617. doi: 10.1136/bmjopen-2024-088617. BMJ Open. 2024. PMID: 39632113 Free PMC article.
-
Does a Survivorship Model of Opioid Use Disorder Improve Public Stigma or Policy Support? A General Population Randomized Experiment.J Gen Intern Med. 2023 May;38(7):1638-1646. doi: 10.1007/s11606-022-07865-y. Epub 2022 Nov 17. J Gen Intern Med. 2023. PMID: 36394698 Free PMC article. Clinical Trial.
References
-
- Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2019. Accessed July 30, 2020. https://www.samhsa.gov/data/
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. American Psychiatric Association; 2013. doi:10.1176/appi.books.9780890425596
-
- Martins SS, Sarvet A, Santaella-Tenorio J, Saha T, Grant BF, Hasin DS. Changes in US Lifetime Heroin Use and Heroin Use Disorder: Prevalence From the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatr. 2017;74(5):445–455. doi: 10.1001/jamapsychiatry.2017.0113. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical